Clinical Trials Logo

Subjective Cognitive Decline clinical trials

View clinical trials related to Subjective Cognitive Decline.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06358404 Not yet recruiting - Clinical trials for Subjective Cognitive Decline

Developing a Peer Support Intervention for Depression in SCD

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline.

NCT ID: NCT06002477 Not yet recruiting - Clinical trials for Subjective Cognitive Decline

Attentional Mechanisms in SCD

AMoCC-SCD
Start date: June 1, 2024
Phase: Early Phase 1
Study type: Interventional

This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.

NCT ID: NCT05225181 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Effects of the Combining Physical Exercise and Cognitive Training for the Community-based Elderly

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This study aims to (1) determine the intervention effects of sequential and simultaneous training on cognitive function and health-related function for cognitively-normal elderly and elderly with Mild Cognitive Impairment(MCI) and Subjective Cognitive Decline(SCD); (2) compare which combination approach is more advantageous for improvement on outcome measures.

NCT ID: NCT03057938 Not yet recruiting - Clinical trials for Subjective Cognitive Decline

Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study

Start date: August 2018
Phase: Phase 2
Study type: Interventional

Phase II, open-label clinical trial with a medicinal product. A total of 30 subjects will be included in the study. All participants will receive a single intravenous dose of 300 MBq of FBB. A 20-minute PET image should be acquired starting at approximately 90 minutes after intravenous injection of FBB. The present proposal aims are: to assess safety of a single dose of FBB followed by PET scan in individuals with subjective cognitive decline (SCD), to determine the number of SCD subjects with positive visual FBB-PET scan, to determine the number of SCD subjects with positive standardized uptake value ratios (SUVRs) of FBB-PET scan and to explore the cortical pattern of amyloid deposition in SCD subjects.